ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Work Disability"

  • Abstract Number: 702 • 2016 ACR/ARHP Annual Meeting

    Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort

    Pascal Claudepierre1, Filip van Den Bosch2, Piercarlo Sarzi-Puttini3, Shiva Sajjan4, N Vastesaeger5, Marinella Govoni6 and Sumesh Kachroo7, 1Hôpital Henri Mondor, Créteil, France, 2Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, 4Merck & Co., Inc., Kenilworth, NJ, 5Merck Sharp & Dohme, Belgium, Brussels, Belgium, 6Via Tasso 14, Merck Sharp & Dohme, Italy, Cento, Italy, 7CORE, Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: We evaluated the effect of the anti-tumor necrosis factor (TNF) agents, golimumab (GLM) and infliximab (IFX), on healthcare resource utilization (HCRU) and work productivity…
  • Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting

    Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy

    Siri Lillegraven1, Maria Dahl Mjaavatten1, Nina P. Sundlisater1, Anna-Birgitte Aga1, Inge C Olsen2, Till Uhlig1, Daniel H. Solomon3, Tore K Kvien1, Espen A. Haavardsholm1 and the ARCTIC Study Group, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
  • Abstract Number: 2670 • 2016 ACR/ARHP Annual Meeting

    Work Disability in Newly Diagnosed Patients with Primary SjöGren’s Syndrome – a Population-Based Cohort Study

    Thomas Mandl1, Tanja Schjødt Jørgensen2, Marie Skougaard Nielsen2, Peter Olsson1 and Lars Erik Kristensen3, 1Dept of Rheumatology, Skane University Hospital Malmö, Lund University, Malmo, Sweden, 2The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, 3The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark

    Background/Purpose:   To study long-term work disability (WD) and possible predictors in newly diagnosed patients with primary Sjögren’s syndrome (pSS). Methods:   51 pSS patients…
  • Abstract Number: 2730 • 2016 ACR/ARHP Annual Meeting

    Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting

    William Tillett1,2, James Piercy3, Su Chen4 and Fabiana Ganz5, 1Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 2Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Adelphi Real World, Cheshire, United Kingdom, 4AbbVie, North Chicago, IL, 5Neuhofstrasse 23, AbbVie, Baar, Switzerland

    Background/Purpose:  Patients (pts) with psoriatic arthritis (PsA) may experience temporary worsening of symptoms or disease flare, which can be painful enough to interfere with day-to-day…
  • Abstract Number: 3252 • 2016 ACR/ARHP Annual Meeting

    Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis

    Lisa Allyn1, Lisa Zoller1, Catherine L. Backman2,3 and Diane Lacaille4,5, 1The University of British Columbia, Vancouver, BC, Canada, 2Department of Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, 3Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 4Medicine, University of British Columbia, Vancouver, BC, Canada, 5Arthritis Research Canada, Richmond, BC, Canada

    Background/Purpose:  Work cessation and at-work productivity loss are common and early outcomes of inflammatory arthritis (IA). Ergonomic accommodations contribute to successful management of arthritis symptoms…
  • Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting

    Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol

    Désirée van der Heijde1, Juergen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Klinikum Bielefeld, Bielefeld, Germany, 4UCB Pharma, Brussels, Belgium, 5University of California San Diego, La Jolla, CA

    Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
  • Abstract Number: 2481 • 2015 ACR/ARHP Annual Meeting

    Work Disability in a Cohort of Patients with Psoriatic Arthritis

    Cecilia Zaffarana1, Osvaldo Luis Cerda1, Josefina Gallino Yanzi1, Margarita Landi1, Emilce Schneeberger1, Ignacio Carrillo1, María del Carmen Gonzalez Guzmán1, Jose A Maldonado Cocco1, Susana Gagliardi1 and Gustavo Citera2, 1Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina

    Background/Purpose: Several studies showed that unemployment and work disability are high in patients with Psoriatic Arthritis (PsA). Te purpose of this study is to evaluate work…
  • Abstract Number: 2648 • 2015 ACR/ARHP Annual Meeting

    Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy

    Vappu Rantalaiho1, Marjatta Leirisalo-Repo2, Hannu Kautiainen3, Petri Mankinen4, Janne Martikainen5 and Kari Puolakka6, 1Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, 2Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 4Pharmacoeconomics & Outcomes Research Unit (PHORU), School of Pharmacy, University of Eastern Finland, Kuopio, Finland, 5Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, 6Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland

    Background/Purpose: To evaluate vitality, reduced paid and unpaid work ability, and productivity losses for patients with early rheumatoid arthritis (RA) available for work force at…
  • Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting

    Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Arthur Kavanaugh1, Dafna Gladman2, Désirée van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1University of California San Diego, La Jolla, CA, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Rheumatology Research, Swedish Medical Center, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
  • Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting

    Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

    Robert Morlock1, Natalia M. Flores2, Kathy Annunziata3, J. Chapnick4 and Sulabha Ramachandran5, 14939 Directors Place, Ardea Biosciences, San Diego, CA, 2Kantar Health, Foster City, CA, 3Kantar Health, Princeton, NJ, 4Kantar Health, Horsham, PA, 5AstraZeneca, Wilmington, DE

    Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
  • Abstract Number: 2560 • 2014 ACR/ARHP Annual Meeting

    Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Desiree van der Heijde1, Juergen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum, Berlin, Germany, 4Allee De La Recherche 60, UCB Pharma, Anderlecht, Belgium, 5University of California San Diego, La Jolla, CA

    Background/Purpose Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). Previous…
  • Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting

    Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis

    V. Strand1, R. Riese2, R. Gerber2, D. Gruben2, A.G. Bushmakin2, E.Y. Mahgoub3 and G. Wallenstein2, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
  • Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting

    A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)

    Mihir D. Wechalekar1, Steve Quinn2, Susan Lester3, Ella Shanahan4, Robert Metcalf5, E. Michael Shanahan6 and Susanna Proudman4,7, 1Flinders University School of Medicine, Adelaide, Australia, 2Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, 3Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, 4University of Adelaide, Discipline of Medicine, Adelaide, Australia, 5University of Adelaide, Adelaide, Australia, 6Rheumatology, Flinders University, Bedford Park, South Australia, Australia, 7Department of Rheumatology, Royal Adelaide Hospital, SA, Australia

    Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
  • Abstract Number: 1552 • 2014 ACR/ARHP Annual Meeting

    Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis

    Arthur Kavanaugh1, Dafna D. Gladman2, Désirée van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1University of California San Diego, La Jolla, CA, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 The previous results…
  • Abstract Number: 577 • 2014 ACR/ARHP Annual Meeting

    A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort

    A Roeterink1, M de Hooge2, R. van den Berg2, H Dagfinrud3, M Turina4, M. van Oosterhout5, D. van der Heijde1 and F van Gaalen2, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, 4Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Groene Hartziekenhuis, Gouda, Netherlands

    Background/Purpose: Ankylosing spondylitis is associated with work productivity (WP) loss and a decreased health-related quality of life (HRQoL).  Little is known about WP loss and…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology